Compounds > inflachromene
Page last updated: 2024-11-13

inflachromene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

inflachromene: has anti-inflammatory activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID49857340
CHEMBL ID1801580
SCHEMBL ID17518099
MeSH IDM000601647

Synonyms (12)

Synonym
CHEMBL1801580
inflachromene
908568-01-4
SCHEMBL17518099
5-hydroxy-9,9-dimethyl-15-phenyl-8-oxa-13,15,17-triazatetracyclo[8.7.0.0,.0,heptadeca-2(7),3,5,10-tetraene-14,16-dione
AS-16939
10-hydroxy-7,7-dimethyl-2-phenyl-7,12b-dihydrochromeno[4,3-c][1,2,4]triazolo[1,2-a]pyridazine-1,3(2h,5h)-dione
AKOS037643571
AC-36952
HY-113772
5-hydroxy-9,9-dimethyl-15-phenyl-8-oxa-13,15,17-triazatetracyclo[8.7.0.02,7.013,17]heptadeca-2(7),3,5,10-tetraene-14,16-dione
CS-0063284
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID1460206Stability in human liver microsomes assessed as compound remaining preincubated for 5 mins followed by NADPH addition measured after 30 mins LC/MS/MS method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID1460191Anti-inflammatory activity in C57BL/6(B6) mouse model of CLP-induced sepsis assessed as decrease in serum IL-6 level at 10 mg/kg, ip administered daily for 9 days starting from 1 hr prior to CLP-induction by ELISA2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID604512Inhibition of MMP-7 mRNA expression in mouse RAW264.7 cells at 10 uM by RT-PCR analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID604508Inhibition of RANKL-induced osteoclastogenesis in BALB/c mouse Bone marrow macrophages assessed as decrease in TRAP-positive cells after 1 hr by microplate reader assay2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID604511Inhibition of c-Src mRNA expression in mouse RAW264.7 cells at 10 uM by RT-PCR analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID1460208Cmax in ICR mouse at 10 mg/kg, ip by LC/MS/MS method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID1460203Inhibition of NF-kappaB p65 nuclear translocation in LPS-stimulated mouse RAW264.7 cells at 20 uM pretreated followed by LPS-induction by Hoechst 33342/TRITC staining based immunofluorescence microscopic method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID1460205Stability in mouse liver microsomes assessed as compound remaining preincubated for 5 mins followed by NADPH addition measured after 30 mins LC/MS/MS method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID604516Downregulation of RANKL-induced fra2 mRNA expression in mouse RAW264.7 cells at 10 uM by RT-PCR analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID604507Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive cells after 1 hr by microplate reader assay2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID1460196Inhibition of HMGB1 nuclear translocation in LPS-stimulated mouse RAW264.7 cells at 20 uM pretreated for 1 hr followed by LPS-induction measured after 2 hrs by Hoechst 33342/TRITC staining based immunofluorescence microscopic method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID1460197Inhibition of HMGB1 nuclear translocation in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of IL-6 production at 10 uM pretreated for 1 hr followed by LPS-induction by Western blot analysis2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID1460190Anti-inflammatory activity in C57BL/6(B6) mouse model of CLP-induced sepsis assessed as increase in survival rate at 10 mg/kg, ip administered daily for 9 days starting from 1 hr prior to CLP-induction2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID1460202Inhibition of ERK phosphorylation in LPS-stimulated mouse RAW264.7 cells at 20 uM pretreated followed by LPS-induction by Western blot analysis2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID1460211Anti-inflammatory activity in C57BL/6(B6) mouse model of CLP-induced sepsis assessed as survival rate at 10 mg/kg, ip administered daily for 21 days starting from 1 hr prior to CLP-induction (Rvb = 10 %)2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID1460210Half life in ICR mouse at 10 mg/kg, ip by LC/MS/MS method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID604513Inhibition of TRAP mRNA expression in mouse RAW264.7 cells at 10 uM by RT-PCR analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID1460212Anti-inflammatory activity in C57BL/6(B6) mouse model of CLP-induced sepsis assessed as decrease in serum IL-6 level at 10 mg/kg, ip administered daily for 21 days starting from 1 hr prior to CLP-induction by ELISA2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID604514Downregulation of RANKL-induced c-fos mRNA expression in mouse RAW264.7 cells at 10 uM by RT-PCR analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID1460193Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 10 uM in presence of LPS measured after 24 hrs by WST assay relative to control2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID604505Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 30 uM after day 1 by CCK-8 assay2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID1460198Inhibition of ICM-BP binding to recombinant human HMGB1 assessed as reduction in Cy5-azide incorporation pretreated for 60 mins followed by ICM-BP addition for 20 mins and subsequent UV light irradiation for 5 mins by fluorescence assay2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID604515Downregulation of RANKL-induced NFATc1 mRNA expression in mouse RAW264.7 cells at 10 uM by RT-PCR analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID604509Inhibition of NFkappa signaling in mouse RAW264.7 cells assessed as reduction in RANKL-induced transcriptional activation on NF-kappaB by luciferase reporter gene assay2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID604518Inhibition of RANKL-induced p38 phosphorylation in mouse RAW264.7 cells at 10 uM by Western blot analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID604506Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 30 uM after day 4 by CCK-8 assay2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID1460207Tmax in ICR mouse at 10 mg/kg, ip by LC/MS/MS method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID1460192Inhibition of HMGB1 translocation from nucleus to cytosol in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO release at 10 uM measured after 24 hrs by Griess assay relative to control2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID604517Inhibition of RANKL-induced ERK phosphorylation in mouse RAW264.7 cells at 10 uM by Western blot analysis2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID1460209AUC in ICR mouse at 10 mg/kg, ip by LC/MS/MS method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID1460201Inhibition of JNK phosphorylation at Thr183/Tyr185 resdiues in LPS-stimulated mouse RAW264.7 cells at 20 uM pretreated followed by LPS-induction by Western blot analysis2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID1460204Equilibrium aqueous solubility of the compound by microsol method2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID604504Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as TRAP-positive cells at 10 uM after 1 hr by microplate reader assay2010Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24
Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand.
AID1460200Inhibition of MAPK p38 phosphorylation at Thr180/Tyr182 resdiues in LPS-stimulated mouse RAW264.7 cells at 20 uM pretreated followed by LPS-induction by Western blot analysis2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
AID1460195Inhibition of HMGB1 translocation from nucleus to cytosol in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of TNF-alpha production at 10 uM measured after 4 hrs by ELISA relative to control2017Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1
Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (70.00)24.3611
2020's3 (30.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.64 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index5.40 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
kainic acid
Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.		2.610dicarboxylic acid;
L-proline derivative;
non-proteinogenic L-alpha-amino acid;
pyrrolidinecarboxylic acid		antinematodal drug;
excitatory amino acid agonist
angiotensin ii
Giapreza: injectable form of angiotensin II used to increase blood pressure in adult patients with septic or other distributive shock. Ile(5)-angiotensin II : An angiotensin II that acts on the central nervous system (PDB entry: 1N9V).		2.610amino acid zwitterion;
angiotensin II		human metabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Poisoning
[description not available]		02.1510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.6620
Sepsis
Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.		02.1510
Aura
[description not available]		02.610
Epilepsy
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)		07.610
Hyperplasia
An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.		07.610
Innate Inflammatory Response
[description not available]		02.110
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.110